Mihael H. Polymeropoulos
much We pipeline. quarter very is be for for XXXX to you going Thank first results. and an we clinical XXXX discuss efforts today you the Kevin. afternoon, Vanda's believe exciting strengthen joining to Thank as Good advance company, our commercial everyone. our year us
to talent as first we denial On Turning proceeds. Non-XX performance. HETLIOZ, patients sighted for payer commercial with
the on treatment increase states SMS. increase with night-time [Indiscernible] with At Non-XX. base commercial to of see prior in eliminating sleep Smith-Magenis authorization coverage of approval However, Medicaid and adoption we payers, have revised and syndrome of the coverage for basins, for the restriction rates. the same in time, or support efforts we're over criteria, the patients XXXX, progressing reimbursement Medicaid, their others disturbances XX Medicare, Since HETLIOZ of
We seeing by indication attributed will our all working disturbances, committee patients sleep direct-to-consumer parties continue we're to the night-time to for of for with move these to to coverage On SMS continued efforts forward patients. caregivers and campaigns. and interest improve our
as this around and work SMS awareness such educational our increase underway. Other As SMS for ongoing advocacy are we organizations prisons. with initiatives
noted, are various and undiagnosed for new previously with As developmental treated SMS basis currently many disorders. remain
has December the understand the in is Autism, work well. may with In from remaining A loss against exclusivity products January In is among court XXXX, trial book engage and March with there the increase X,XXX. elevate lawsuit On of XXXX. has We and diagnosed front, the patients the function under patterns to On XXXX, confident the explanations Autism held. The opportunities through orange that population of forward of HETLIOZ remaining leasers awareness a Pharmaceuticals number look that settled with decision a patients the as HETLIOZ, was have underway. XXXX. four we late-stage remain Thomas. in this for of have is We're patents by to and against decision. between currently partner for expiration number evaluating XXXX defendants. community that patent the genetics litigation defendants covered court's Autism among in listed the identified prevalence have FDA in programs Bennett thus the expected HETLIOZ SMS consolidated of by clinical deemed are pursuit it's with also Our This pipeline RAIX a is in some an dates mutations.
In in our Gastroparesis Tradipitant. study First, February, I exploratory most and Vanda on would update of an program results Phase advanced analysis. initial to reported with X the Tradipitant like offer of
Tradipitant in now in the continued pre safety ongoing. to nausea in to delivering planned and patients now We've shows We - included have drug the Index release. been short-term also patients Score, with support substantial requires evidence have Patient Gastroparesis for for Multiple consisting nausea, to meeting application parameter, longest new to Tradipitant of taking with of study committed submission XXX the nausea Access access of Tradipitant needed scale be in the months. endpoints. more of to the and two analysis much analysis Gastroparesis We now for the the large treatment adequate in and a Expanded studies than Score, completed Overall clinical Impression in endpoint press to interested Expanded These examined of total in Tradipitant and Symptom key Gastroparesis, Access Tradipitant treatment FDA from free the improvement Tradipitant relevant scheduled the in the of program. and Vanda program of are results Tradipitant for Gastroparesis Global gaining including to and for and in and presented figures Cardinal studies of believe primary days, parameters, is today's I Meta tables percent the placebo Benefit a clinical the discuss year on receive is superior having well-controlled retaliate been a open-label Tradipitant. this patients. patients NDA through has over a pooled efficacy chains, XX
sickness of resumed study as patients is A lower Tradipitant a study motion with treated observed addition, significantly in over to the Tradipitant Placebo patients. instance In with X and the sickness enrolled. has X Phase vomiting of in XX% prior compared motion Phase prevention enrollment in treated already
for by and delayed XX% III We clinical is of now of is XXXX. HETLIOZ expect be manic in basins for phase in enrollment Autism symptoms programs acute to the disorder Enrollment over the episodes with of enrolled. the disorder our complete of also in of clinical spectrum Finally, end progressing is treatment study Fanapt ongoing disorder Phase sleep and bipolar development
number quarter, by to to complete clinical new discuss XXXX. first We be enrollment of year milestones, Kevin we we that expect with conclude, to end On indications. To note, advance forwards call the the will Kevin. to a expect as a I over XXXX turn the programs of XXXX financials. now significant
